An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia

NCT01894984 · clinicaltrials.gov ↗

TERMINATED

Status

640

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated because of high dropout rate.

Conditions

Schizophrenia

Interventions

DRUG: Risperidone
DRUG: Oral atypical anti-psychotic

Sponsor

Xian-Janssen Pharmaceutical Ltd.